NEWTON, Mass., May 30, 2024 /PRNewswire/ -- 4D Path ('the Company'), a company dedicated to personalizing cancer care through their advanced approach to predicting tumor response, is pleased to announce today new clinical data highlighted in two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 – June 4, 2024 at McCormick Place, Chicago, IL.

马萨诸塞州牛顿市，2024年5月30日/PRNewswire/-4D Path（“该公司”）是一家致力于通过先进的预测肿瘤反应的方法来个性化癌症治疗的公司，今天很高兴在2024年5月31日至6月4日于伊利诺伊州芝加哥市麦考密克广场举行的2024年美国临床肿瘤学会（ASCO）年会上宣布两篇摘要中强调的新临床数据。

These studies were conducted utilizing 4D Path's patented Q-Plasia OncoReader (QPOR™), a groundbreaking platform designed to directly measure and quantify cell cycle deregulations and tumor microenvironment dynamics to accurately predict a patient's response to therapy. The QPOR platform allows clinicians, cancer researchers, and drug developers to see beyond a cancer biomarker and uncover the cell cycle deregulations that are distinct to an individual tumor..

这些研究是利用4D Path获得专利的Q-Plasia OncoReader（QPOR™）进行的，该平台是一个开创性的平台，旨在直接测量和量化细胞周期失调和肿瘤微环境动力学，以准确预测患者对治疗的反应。QPOR平台允许临床医生，癌症研究人员和药物开发人员超越癌症生物标志物，揭示不同于个体肿瘤的细胞周期失调。。

'This is an important milestone for 4D Path, as this data validates how 4D Path's Q-Plasia OncoReader platform (QPOR) will help pioneer a new generation of truly personalized and deeply targeted cancer therapies through an automated computational assessment of collective tumor states,' stated Satabhisa Mukhopadhyay, PHD, Chief Scientific Officer and Co-Founder of 4D Path.

“这是4D Path的一个重要里程碑，因为这些数据验证了4D Path的Q-Plasia OncoReader平台（QPOR）将如何通过对集体肿瘤状态的自动计算评估来帮助开创新一代真正个性化和深度靶向的癌症治疗，”4D Path首席科学官兼联合创始人Satabhisa Mukhopadhyay博士说。

'Despite recent technological advancements, we are still faced with significant limitations in terms of personalized cancer treatments. The QPOR platform's novel approach to viewing the dynamics of the tumor state gives clinicians, researchers, and drug developers the insight into a specific patient's cell cycle deregulations and its interactions with tumor immune microenvironment, therefore allowing us to be more effective and specific when developing and implementing treatments.'.

“尽管最近取得了技术进步，但我们在个性化癌症治疗方面仍面临重大限制。QPOR平台观察肿瘤状态动态的新方法使临床医生，研究人员和药物开发人员能够深入了解特定患者的细胞周期失调及其与肿瘤免疫微环境的相互作用，因此使我们在开发和实施治疗时更有效和特异性。

'This represents a potential major step closer towards truly personalized cancer therapies,' stated Craig A. Bunnell, MD, MPH, MBA, Morse Family Chief Medical Officer, Dana-Farber Cancer Institute. 'Cancer is an incredibly personal disease, and the best way to fight it is through personalized and targeted treatments.

达纳法伯癌症研究所莫尔斯家族首席医疗官、医学博士、公共卫生硕士、工商管理硕士克雷格·邦内尔（CraigA.Bunnell）表示：“这意味着朝着真正个性化的癌症治疗迈出了潜在的重要一步。”。癌症是一种令人难以置信的个人疾病，对抗它的最佳方法是通过个性化和有针对性的治疗。

These data showcase consequential progress towards precision medicine and being able to provide patients personalized, highly targeted therapies based on their specific cancer cell signatures.' .

这些数据展示了精准医学取得的重大进展，并能够根据患者特定的癌细胞特征为患者提供个性化，高度靶向的治疗。”。

'In our analysis of the TBCRC 030 preoperative study, both visual assessment and computational assessment of tumor infiltrating lymphocytes using the QPOR platform were predictive of response to neoadjuvant chemotherapy for triple negative breast cancer,' stated Dr. Erica L. Mayer, MD, MPH, Director of Breast Cancer Clinical Research, Dana-Farber Cancer Institute.

“在我们对TBCRC 030术前研究的分析中，使用QPOR平台对肿瘤浸润淋巴细胞进行视觉评估和计算评估都可以预测对三阴性乳腺癌新辅助化疗的反应，”达纳法伯癌症研究所乳腺癌临床研究主任Erica L.Mayer博士说。

'These findings represent an important step in determining the effectiveness and accuracy of computational biomarker assessments in clinical cancer management.'.

“这些发现代表了确定临床癌症管理中计算生物标志物评估的有效性和准确性的重要一步。”。

'This is an exciting moment for oncology and pathology,' said Stuart J. Schnitt, M.D., Chief of Breast Oncologic Pathology for the Dana-Farber Brigham Cancer Center, Associate Director of the Dana-Farber Cancer Institute/Brigham and Women's Hospital Breast Oncology Program. 'The 4D Path QPOR Platform can potentially help inform researchers and clinicians about which patients are more or less likely to respond to neoadjuvant chemotherapy, paving the path for more precise and personalized treatments for patients.' .

达纳-法伯-布里格姆癌症中心乳腺肿瘤病理学主任、达纳-法伯癌症研究所/布里格姆妇女医院乳腺肿瘤项目副主任斯图尔特·J·施尼特（StuartJ.Schnitt）医学博士说：“这对肿瘤学和病理学来说是一个激动人心的时刻。”4D Path QPOR平台可能有助于告知研究人员和临床医生哪些患者对新辅助化疗有或多或少的反应，为患者进行更精确和个性化的治疗铺平道路。”。

The abstracts listed below will be highlighted at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 – June 4, 2024, at McCormick Place, Chicago, IL.

下面列出的摘要将在2024年5月31日至6月4日在伊利诺伊州芝加哥麦考密克广场举行的2024年美国临床肿瘤学会（ASCO）年会上重点介绍。

Title:

标题：

Correlation of TILs indices generated by visual review and digitalcomputational algorithm with outcomes from preoperativechemotherapy for TNBC in TBCRC 030.

视觉检查和数字计算算法产生的TILs指数与TBCRC 030中TNBC术前化疗结果的相关性。

Date & Time:

日期和时间：

Sunday, June 2, 2024 at 9:00am – 12:00pm CDT (Hall A)

2024年6月2日，星期日，CDT上午9:00至下午12:00（A厅）

Session Type:

会话类型：

Poster Session: Breast Cancer – Local/Regional/Adjuvant

海报环节：乳腺癌-局部/区域/辅助

Abstract Number:

摘要编号：

555

555

Title:

标题：

Automated prediction of response to neoadjuvant chemotherapyfrom digitized H&E slides of pre-treatment biopsies of germline BRCAcarriers with HER2-negative breast cancer (TBCRC 031)

从HER2阴性乳腺癌生殖系BRCA携带者治疗前活检的数字化H＆E载玻片自动预测对新辅助化疗的反应（TBCRC 031）

Date & Time:

日期和时间：

Sunday, June 2, 2024 at 9:00am – 12:00pm CDT (Hall A)

2024年6月2日，星期日，CDT上午9:00至下午12:00（A厅）

Session Type:

会话类型：

Poster Session: Breast Cancer – Local/Regional/Adjuvant

海报环节：乳腺癌-局部/区域/辅助

Abstract Number:

摘要编号：

605

605

About 4D Path4D Path has created a groundbreaking new platform, the patented Q-Plasia OncoReader (QPOR), that is designed to directly measure and quantify cell cycle deregulations and tumor microenvironment dynamics to accurately predict a patient's response to therapy in a way that has never been possible before.

大约4D Path4D Path创建了一个开创性的新平台，即获得专利的Q-Plasia OncoReader（QPOR），该平台旨在直接测量和量化细胞周期失调和肿瘤微环境动力学，以准确预测患者对治疗的反应，这种方式以前从未有过。

This unprecedented view of the dynamics within the tumor state, and the QPOR platform's aim to precisely predict tumor response to therapies, creates pathways for optimization from the clinical setting to commercialization in an effort to bring more targeted treatments to patients. 4D Path is focused on a bold vision where every person impacted by cancer is diagnosed quickly and accurately and receives the best, most personalized treatment plan to beat cancer and live a longer, healthier life..

这种前所未有的肿瘤状态动态视图，以及QPOR平台精确预测肿瘤对治疗反应的目标，为从临床环境到商业化的优化创造了途径，以期为患者带来更有针对性的治疗。4D Path专注于一个大胆的愿景，让每个受癌症影响的人都能快速准确地得到诊断，并获得最佳、最个性化的治疗计划，以战胜癌症，过上更长、更健康的生活。。

For more information on 4D Path and the QPOR platform, please visit: www.4DPath.com

有关4D Path和QPOR平台的更多信息，请访问：www.4DPath.com

Investor / Media Contact:Ethan Metelenis, Precision AQEthan.Metelenis@precisionaq.com

投资者/媒体联系人：Ethan Metelenis，PrecisionAQEthan.Metelenis@precisionaq.com

SOURCE 4D Path

源4D路径